Enonin refers to Idarubicin Hydrochloride for Injection, an anti-cancer injection that is a myelosuppressive agent. Idarubicin Hydrochloride for Injection is a potent myelosuppressant, and as a first-line drug, it is clinically used in the treatment of acute non-lymphoblastic leukemia in adults, and is also used in the treatment of relapsed and refractory patients in induced remission. As a second-line agent, it is mainly used in the treatment of acute lymphoblastic leukemia in children and adults. The adverse effect of this drug is myelosuppression, which is mainly characterized by a decrease in red blood cells, white blood cells, and platelets. It has cardiotoxicity, which is mainly characterized by the possibility of acute arrhythmias, heart failure, and cardiomyopathy. Other adverse reactions include infection, alopecia, nausea, vomiting, anorexia, skin rash, etc. If adverse reactions occur, it is necessary to promptly inform the attending physician for targeted treatment. Idarubicin Hydrochloride for Injection requires exclusion of systemic infections and evaluation of cardiac function prior to administration, and regular testing of blood, liver, kidney, and cardiac function during administration. It should be noted that this drug is contraindicated in patients who are allergic to the components of this drug, patients with severe impairment of liver or kidney function, patients with uncontrolled infection, and breastfeeding women should stop breastfeeding during the administration of this drug.